Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurie Millar

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Annals of the New York Academy of Sciences|February 13, 2003
Cerebellar mechanisms in eyeblink conditioningPhilip J E Attwell, Magnus Ivarsson, Laurie Millar, et al.
Plos One|February 6, 2014
Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III programPaul Emery, William Rigby, Paul P Tak, et al.
The Lancet. Psychiatry|November 7, 2016
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programmeDragana Bugarski-Kirola, Nakao Iwata, Snjezana Sameljak, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Annals of the New York Academy of Sciences|February 13, 2003
Cerebellar mechanisms in eyeblink conditioningPhilip J E Attwell, Magnus Ivarsson, Laurie Millar, et al.
Plos One|February 6, 2014
Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III programPaul Emery, William Rigby, Paul P Tak, et al.
The Lancet. Psychiatry|November 7, 2016
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programmeDragana Bugarski-Kirola, Nakao Iwata, Snjezana Sameljak, et al.
Pageof 1